07/13/21 7:33 AMNasdaq : SLRX Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged SarcomasSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers,RHEA-AIneutral
07/09/21 7:33 AMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare ConferenceSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that David Arthur, Chief Executive Officer,RHEA-AIneutral
06/17/21 8:03 AMNasdaq : SLRX conferencesREMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor EventSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stageRHEA-AIneutral
06/15/21 7:30 AMNasdaq : SLRX clinical trialSalarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic CancersSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stageRHEA-AIneutral
06/10/21 1:30 PMNasdaq : SLRX conferencesSalarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor EventSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stageRHEA-AIneutral
06/07/21 7:35 AMNasdaq : SLRX Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat’s Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual MeetingPresentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial Initial drug activity observed in both relapsed/refractory Ewing sarcoma and AST trials Advanced FET-rearranged sarcoma patients in ASTRHEA-AIneutral
05/19/21 5:01 PMNasdaq : SLRX Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual MeetingPreliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials Presentations include full data from dose-escalation stage of Phase 1/2 clinical trial evaluating seclidemstat in Ewing sarcoma and preliminary data from ongoing AST trial HOUSTON, MayRHEA-AIneutral
05/12/21 4:05 PMNasdaq : SLRX earningsSalarius Pharmaceuticals Reports First Quarter Financial Results with Business HighlightsSalariusRHEA-AIneutral
05/05/21 7:05 AMNasdaq : SLRX conferencesearningsSalarius Pharmaceuticals to Report First Quarter 2021 Financial ResultsSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers,RHEA-AIneutral
04/29/21 7:30 AMNasdaq : SLRX Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual MeetingSalarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts accepted forRHEA-AIneutral